Nuclear Receptor Networks in Mucosal Immune Regulation

粘膜免疫调节中的核受体网络

基本信息

  • 批准号:
    10822885
  • 负责人:
  • 金额:
    $ 42.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-01 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary The gut is a major immunological organ where host-microbe interactions shape both local and systemic immune tolerance. However, current views of intestinal immune regulation ignore fundamental differences in the function and metabolite composition of the two distinct organs that comprise the gut—the small and large intestine (or SI and LI). This impedes a more detailed understanding of immune regulatory mechanisms along the intestinal tract, and limits efforts to develop safer, more targeted treatments for the two major forms of human inflammatory bowel diseases (IBDs), ulcerative colitis and small bowel Crohn’s disease. We hypothesize that mucosal CD4 T cells use different sets of ligand-regulated nuclear receptors (NRs) in the SI and LI to control key regulatory functions, including IL-10 expression, to local concentration gradients of bile- and microbe-derived metabolites. On one hand, we have discovered that Foxp3– effector (Teff) subsets in the SI—including Th1 and Th17 cells— utilize the nuclear xenobiotic receptor, constitutive androstane receptor (CAR/Nr1i3), to direct a ‘hepatocyte-like’ transcriptional response to contend with high local bile acid (BA) concentrations, which are far greater in SI than in LI (millimolar vs micromolar) due to ‘enterohepatic’ circulation—where primary BAs synthesized in the liver, stored in the gallbladder, and secreted into the duodenum are actively reabsorbed by specialized enterocytes in the ileum for portal recirculation to the liver. Because BAs are lipophilic, they can be toxic and pro-inflammatory, and several nuclear receptors—including CAR—have evolved to suppress BA toxicity. These studies suggest that enterohepatic circulation establishes a unique SI microenvironment that is distinct from that in the LI and requires unique transcriptional machinery to protect T cells in the SI. Conversely, the LI harbors 103-107 times more bacteria than SI, and ~1000-fold lower BA concentrations. Accordingly, microbes and their metabolites— short chain fatty acids (SCFAs; e.g., butyrate), secondary BAs (produced via microbial metabolism of residual primary BAs)—are central to immune regulation in the LI. SCFAs inhibit histone deacetylase enzymes (HDACs) and stabilize Foxp3 gene expression in peripherally-induced T regulatory cells (iTregs), whereas secondary BAs appear to promote regulatory functions of RORgt+ Tregs in the LI through another NR, vitamin D receptor (VDR). Thus, while antigens from the enteric flora prime both pro- and anti-inflammatory T cell responses throughout the gut, marked concentration gradients of bile- and bacteria-derived metabolites in the SI vs. LI are sensed by different NRs to execute compartmentalized T cell regulatory functions. In testing this hypothesis, we will apply cutting-edge genomics and computational approaches to comprehensively map the contributions of each of the 49 mouse NRs to specialized regulatory functions in the SI and LI in vivo, using IL-10 expression as the primary screening target. We will also interrogate the regulation and molecular functions of two key NRs, CAR/Nr1i3 and VDR/Nr1i1, in SI type 1 regulatory (Tr1) and LI iTreg cells, respectively. These studies will advance understanding of lymphocyte specialization in the gut, and inform new approaches to treat IBDs.
项目摘要 肠道是一个主要的免疫器官,宿主-微生物相互作用塑造了局部和全身免疫 宽容然而,目前关于肠道免疫调节的观点忽视了功能上的根本差异, 以及组成肠的两个不同器官-小肠和大肠(或SI)的代谢物组成 和LI)。这阻碍了对沿着肠道免疫调节机制的更详细的了解。 道,并限制了努力开发更安全,更有针对性的治疗两种主要形式的人类炎症 肠道疾病(IBD)、溃疡性结肠炎和小肠克罗恩病。我们假设粘膜CD 4 T细胞 细胞在SI和LI中使用不同的配体调节的核受体(NRs)组来控制关键的调节 功能,包括IL-10的表达,局部浓度梯度的胆汁和微生物衍生的代谢物。 一方面,我们已经发现SI中的Foxp 3效应子(Teff)亚群-包括Th 1和Th 17细胞- 利用核异生素受体,组成型雄烷受体(CAR/Nr 1 i3),指导“肝细胞样” 转录反应,以抗衡高局部胆汁酸(BA)浓度,这是远远大于SI比 在由于“肠肝”循环的LI(毫摩尔对微摩尔)中-其中初级BA在肝脏中合成, 储存在胆囊中,并分泌到十二指肠,被专门的肠细胞积极重吸收, 回肠进行肝门静脉再循环。因为BA是亲脂性的,它们可能是有毒的和促炎的, 并且几种核受体-包括CAR-已经进化为抑制BA毒性。这些研究表明 肝肠循环建立了一个独特的SI微环境,与LI中的微环境不同, 需要独特的转录机制来保护SI中的T细胞。相反,LI港103-107倍 比SI更多的细菌,以及低约1000倍的BA浓度。因此,微生物及其代谢产物- 短链脂肪酸(SCFA;例如,丁酸盐)、次级BAs(通过微生物代谢残留的 初级BA)-是LI中免疫调节的中心。SCFA抑制组蛋白脱乙酰酶(HDAC) 并稳定外周诱导的T调节细胞(iT细胞)中Foxp 3基因的表达,而次级BAs 似乎通过另一种NR维生素D受体(VDR)促进LI中RORgt+ Treg的调节功能。 因此,虽然来自肠道植物群的抗原在整个过程中引发促炎性和抗炎性T细胞应答, 在肠道中,SI与LI中胆汁和细菌衍生代谢物的显著浓度梯度通过 不同的NR执行区室化的T细胞调节功能。为了验证这一假设,我们将 尖端的基因组学和计算方法,以全面绘制每个基因的贡献, 49个小鼠NR在体内SI和LI中具有专门的调节功能,使用IL-10表达作为主要的 筛选目标我们还将询问两个关键NR,CAR/Nr 1 i3和Nr 1 i3的调节和分子功能。 VDR/Nrlii,分别在SI 1型调节性(Trl)和LI iTreg细胞中。这些研究将进一步 了解肠道中淋巴细胞的特化,并为治疗IBD提供新的方法。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Quantifying forms and functions of intestinal bile acid pools in mice.
量化小鼠肠道胆汁酸库的形式和功能。
  • DOI:
    10.1101/2024.02.16.580658
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sudo,Koichi;Delmas-Eliason,Amber;Soucy,Shannon;Barrack,KaitlynE;Liu,Jiabao;Balasubramanian,Akshaya;Shu,ChengyiJenny;James,Michael;Hegner,CourtneyL;Dionne,HenryD;Rodriguez-Palacios,Alexander;Krause,Henry;O'Toole,GeorgeA;Karpe
  • 通讯作者:
    Karpe
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Matthew Eugene Pipkin其他文献

Matthew Eugene Pipkin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Matthew Eugene Pipkin', 18)}}的其他基金

Nuclear Receptor Networks in Mucosal Immune Regulation
粘膜免疫调节中的核受体网络
  • 批准号:
    10591752
  • 财政年份:
    2021
  • 资助金额:
    $ 42.56万
  • 项目类别:
Nuclear Receptor Networks in Mucosal Immune Regulation
粘膜免疫调节中的核受体网络
  • 批准号:
    10459564
  • 财政年份:
    2021
  • 资助金额:
    $ 42.56万
  • 项目类别:
Nuclear Receptor Networks in Mucosal Immune Regulation
粘膜免疫调节中的核受体网络
  • 批准号:
    10283045
  • 财政年份:
    2021
  • 资助金额:
    $ 42.56万
  • 项目类别:
Transcription factor regulation of CD4 and CD8 T cell effector and memory differentiation and function
CD4 和 CD8 T 细胞效应及记忆分化和功能的转录因子调节
  • 批准号:
    10488579
  • 财政年份:
    2020
  • 资助金额:
    $ 42.56万
  • 项目类别:
shRNAmir and CRISPR sgRNA Library Construction Core
shRNAmir 和 CRISPR sgRNA 文库构建核心
  • 批准号:
    10591867
  • 财政年份:
    2020
  • 资助金额:
    $ 42.56万
  • 项目类别:
shRNAmir and CRISPR sgRNA Library Construction Core
shRNAmir 和 CRISPR sgRNA 文库构建核心
  • 批准号:
    10224890
  • 财政年份:
    2020
  • 资助金额:
    $ 42.56万
  • 项目类别:
shRNAmir and CRISPR sgRNA Library Construction Core
shRNAmir 和 CRISPR sgRNA 文库构建核心
  • 批准号:
    10024585
  • 财政年份:
    2020
  • 资助金额:
    $ 42.56万
  • 项目类别:
Transcription factor regulation of CD4 and CD8 T cell effector and memory differentiation and function
CD4 和 CD8 T 细胞效应及记忆分化和功能的转录因子调节
  • 批准号:
    10683256
  • 财政年份:
    2020
  • 资助金额:
    $ 42.56万
  • 项目类别:
Gene expression, Epigenetics and Bioinformatics Core
基因表达、表观遗传学和生物信息学核心
  • 批准号:
    10591868
  • 财政年份:
    2020
  • 资助金额:
    $ 42.56万
  • 项目类别:
shRNAmir and CRISPR sgRNA Library Construction Core
shRNAmir 和 CRISPR sgRNA 文库构建核心
  • 批准号:
    10488582
  • 财政年份:
    2020
  • 资助金额:
    $ 42.56万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 42.56万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 42.56万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 42.56万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 42.56万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 42.56万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 42.56万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 42.56万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 42.56万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 42.56万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 42.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了